Drug-resistant TB (DR-TB) strains are more difficult to treat than drug-susceptible strains, endangering worldwide progress toward the goals established by the WHO's End TB Strategy. Evidence-based policy recommendations for the care and treatment of DR-TB patients are therefore desperately needed. Methods: 139 Patients of Rifampicin-resistant TB on all oral longer MDR regimen (AOLMR) were enrolled under NTEP from 2020 to 2022 were selected retrospectively. Results: Out of 139 enrolled patients, 50 (35%) were cured, 38(27%) completed treatment,19 (13%) were lost to follow up, 28 (20%) died and 4 (0.02%) failed treatment.Out of 90 reported ADRs, QTc prolongation {N=30 (33%)} and peripheral neuropathy {N=17 (18%)} were majority of the side effects. Conclusion: Patients with MDR TB had poor treatment outcomes from the standardized regimen. One of the biggest obstacles to a successful outcome is the length of therapy and defaulters.